SEQSTER Unveils AI-Powered Patient Screening for Clinical Trials

Audio By Carbonatix

SAN DIEGO--(BUSINESS WIRE)--Mar 26, 2026--

SEQSTER PDM, Inc. (“ SEQSTER ”), the leading healthcare technology company powering the connection, collection, and orchestration layer of patient health data, today launched 1-Click Eligibility, an AI solution that helps research teams identify eligible clinical trial participants in minutes. Early deployments have already accelerated drug development timelines.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326385458/en/

Clinical trial recruitment remains one of the most persistent barriers to bringing new therapies to market, with nearly 80% of trials failing to meet enrollment timelines. 1-Click Eligibility helps address this by enabling research teams to enter trial criteria in everyday language and instantly scan patient populations, while AI analyzes longitudinal, patient-consented health data across SEQSTER’s network to identify eligible patients. Patients screened by the platform are ranked with confidence scores based on data recency and completeness. Patient records are then converted into FDA-compliant, research-ready formats, with identifiable information shared only with authorized study personnel after consent is obtained.

The life sciences industry has long required a more sophisticated approach to identifying and engaging eligible patients with greater speed. Despite significant investment in clinical development, a staggering number of trials continue to struggle or fail because locating qualified patients remains a critical bottleneck. 1-Click Eligibility addresses this challenge directly by replacing inefficient manual screening and accelerating timelines to move life-changing research forward.

Studies with pharmaceutical and biotech sponsors, contract research organizations (CROs), and health systems are already demonstrating the platform’s impact in improving time to trial. In a deployment with a leading pharmaceutical company, 1-Click Eligibility screened more than 10,000 patients and identified eligible participants in under an hour, enabling the research team to accelerate trial timelines by nearly 6 months.

“Too many patients miss out on the opportunity to participate in clinical trials simply because researchers can’t find them,” said Ardy Arianpour, CEO & Co-Founder of SEQSTER. “With 1-Click Eligibility, that no longer has to be the case. We look forward to continuing our work with sponsors across the ecosystem to move studies forward faster, improve trial diversity, and ensure more patients have the opportunity to contribute to potentially life-changing research.”

1-Click Eligibility is the latest addition to SEQSTER’s growing 1-Click Solution Suite. For more information, please visit www.seqster.com or contact [email protected].

ABOUT SEQSTER

SEQSTER is the leading healthcare technology company that connects, collects, and refines patient-consented health data across care settings into a unified, longitudinal patient view.

With 150 million patients in its regulatory-grade platform, life sciences companies can accelerate research, AI developers can train higher-quality models, and patients can gain meaningful insights to better manage their health, all from consented, standardized health data.

Founded in 2016, SEQSTER is shaping a new era in healthcare by connecting patients, data, and AI to enable faster, smarter, and more trustworthy clinical and research decisions.

Learn more: [email protected] | www.seqster.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20260326385458/en/

CONTACT: SEQSTER Media Contact:

Caroline Rueve

[email protected]

847.609.4055

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: TECHNOLOGY RESEARCH CLINICAL TRIALS HEALTH TECHNOLOGY BIOTECHNOLOGY HEALTH DATA MANAGEMENT SCIENCE ARTIFICIAL INTELLIGENCE

SOURCE: SEQSTER PDM, Inc.

Copyright Business Wire 2026.

PUB: 03/26/2026 09:00 AM/DISC: 03/26/2026 09:02 AM

http://www.businesswire.com/news/home/20260326385458/en